Homeodent® + 1.4% Sodium Bicarbonate solution
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Oropharynx Cancer
Conditions
Oropharynx Cancer, Hypopharynx Cancer
Trial Timeline
May 1, 2009 → Aug 1, 2011
NCT ID
NCT01066741About Homeodent® + 1.4% Sodium Bicarbonate solution
Homeodent® + 1.4% Sodium Bicarbonate solution is a phase 3 stage product being developed by Boiron for Oropharynx Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01066741. Target conditions include Oropharynx Cancer, Hypopharynx Cancer.
What happened to similar drugs?
0 of 1 similar drugs in Oropharynx Cancer were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01066741 | Phase 3 | Terminated |
Competing Products
5 competing products in Oropharynx Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Nivolumab + Cetuximab | Eli Lilly | Phase 1/2 | 32 |
| Nivolumab + Carboplatin + Paclitaxel | Bristol Myers Squibb | Phase 2 | 35 |
| ISA101b + Cemiplimab | Regeneron Pharmaceuticals | Phase 2 | 31 |
| ISA101b | Regeneron Pharmaceuticals | Phase 2 | 31 |
| SGX942 + Placebo | Soligenix | Phase 3 | 30 |